Novavax announces publication of H1N1 study

Novavax, Inc., has published results of a pandemic H1N1 vaccine pre-clinical trial in the May 12 online edition of the journal Vaccine.

“This study demonstrated in real time the ability of our influenza VLP technology to respond quickly with an effective vaccine in the face of an influenza pandemic,” Dr. Rahul Singhvi, Novavax's president and CEO, said. “We are pleased with the publication of this important study.”

According to the study, Novavax officials produced and delivered a 2009 H1N1 influenza VLP vaccine to the U.S. Centers for Disease Control.

Ferrets were immunized by CDC scientists with 3.75, 7.5 and 15.0 mcg doses of the Novavax vaccine, according to the study. The ferrets were then boosted with a second dose after three weeks. All vaccinated animals developed protective levels of immunity.

Control animals that did not receive the vaccine were not protected and became ill.

“This study demonstrates that effective immunity to H1N1 pandemic virus can be achieved in ferrets by VLP vaccination, resulting in significant protection and viral clearance from the upper and lower respiratory tracts,” the study said.

“Recombinant VLP vaccines are non-infectious and have advantages in safety and manufacturing," the study reported. "They circumvent problems like slow growth, unpredictable yields and mutations during host adaption. Thus, rapid response immunization strategy for pandemic influenza outbreaks could include the preparation of VLP vaccine for prevention of disease in people.”